RT Journal Article
SR Electronic
T1 Validity of HB-EGF as Target for Human Neuroblastoma Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4433
OP 4440
VO 35
IS 8
A1 SUNG OUK NAM
A1 FUSANORI YOTSUMOTO
A1 KOHEI MIYATA
A1 RYOTA SOUZAKI
A1 TOMOAKI TAGUCHI
A1 MASAHIDE KUROKI
A1 SHINGO MIYAMOTO
YR 2015
UL http://ar.iiarjournals.org/content/35/8/4433.abstract
AB Background/Aim: Neuroblastoma (NB) is the most common and lethal extracranial solid tumor in children. The present study aimed to verify that the heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target in NB therapy. Material and Methods: We examined expression of EGFR ligands in four NB cell lines using 2-dimensional culture (DC) and 3DC conditions. To assess the anti-tumor effect of cross-reacting material 197 (CRM197), which is a specific inhibitor of HB-EGF, on NB cells, we also performed terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay to detect apoptotic cells. Results: HB-EGF was predominantly expressed in two out of four NB cell lines under 2DC and 3DC conditions. CRM197 significantly induced apoptosis of NB cells with high HB-EGF expression. Conclusion: HB-EGF plays an important role in neuroblastoma tumorigenesis and CRM197 showed an effective antitumor effect in neuroblastoma cells.